Pre-Surgical Respiratory Muscle Training for Lung Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial studies how well respiratory muscle training before surgery works in preventing lung complications after surgery in patients with stage I-IIIB lung cancer. Patients with lung cancer who choose to undergo surgical resection often have complications after surgery such as pneumonia, unplanned intubations, difficulty breathing and reduced physical functioning, and increased medical costs and a reduced quality of life. Improving pre-surgical pulmonary health through respiratory muscle training may improve respiratory muscle strength, response to surgery, and quality of life after surgery in patients with lung cancer.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial investigators for guidance.
What data supports the idea that Pre-Surgical Respiratory Muscle Training for Lung Cancer is an effective treatment?
The available research shows that Pre-Surgical Respiratory Muscle Training (RMT) can be effective for lung cancer patients. One study found that RMT, when combined with breathing exercises and early movement, improved oxygen levels in high-risk patients after lung cancer surgery. Another study indicated that RMT could help maintain the strength of breathing muscles in patients undergoing lung surgery. Additionally, a comparison of RMT with aerobic exercise training suggested that RMT might offer better post-surgery outcomes for patients having lung surgeries. These findings suggest that RMT can help improve breathing and recovery in lung cancer patients.12345
What safety data exists for respiratory muscle training in lung cancer patients?
The safety of respiratory muscle training (RMT) in lung cancer patients has been evaluated in various studies. A meta-analysis suggests that perioperative RMT can improve respiratory muscle strength and physical activity in patients undergoing lung surgery. A randomized controlled trial found that postoperative inspiratory muscle training (IMT) improved oxygenation in high-risk lung cancer surgery patients, potentially reducing postoperative pulmonary complications. Additionally, a pilot study indicated that IMT with pulmonary rehabilitation might enhance respiratory muscles and exercise capacity in non-small cell lung cancer patients during radiotherapy. While these studies highlight potential benefits, they also imply that RMT is generally safe for lung cancer patients, though adherence to training can be a challenge.12467
Is the treatment in the trial 'Pre-Surgical Respiratory Muscle Training for Lung Cancer' a promising treatment?
Research Team
Saikrishna S. Yendamuri
Principal Investigator
Roswell Park Cancer Institute
Eligibility Criteria
This trial is for patients with stage I-IIIB lung cancer, who can understand English and are set to have curative surgery (VATS or laparoscopic). It includes those who've had chemoradiotherapy. Excluded are pregnant women, those too frail, with poor performance status (ECOG > 2), or serious heart issues.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preoperative Respiratory Muscle Training
Participants use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes, 6 days per week for 2-4 weeks prior to surgery
Surgery
Participants undergo video-assisted thoracic surgery or laparoscopic surgery
Postoperative Monitoring
Participants continue to track activity using a Fitbit for 3 months post-surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Respiratory Muscle Training (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor
Dr. Julia Faller
Roswell Park Cancer Institute
Chief Medical Officer since 2024
DO from an unspecified institution
Dr. Candace S. Johnson
Roswell Park Cancer Institute
Chief Executive Officer since 2015
PhD in Immunology from The Ohio State University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School